Natco Pharma receives approval for generic version of ledipasvir+sofosbuvir tablets in India

15 Dec 2015 Evaluate

Natco Pharma has received approval for the generic version of ledipasvir+sofosbuvir combination from Drugs Controller General (India). The company plans to launch this combination drug immediately, under its brand name Hepcinat LP, and through its strategic partners in India. Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences, Inc., under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. This single-tablet regimen is the first of its kind to offer significantly higher cure rates in Genotype-1 CHC infection compared to conventional therapies.

The company will price its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets. The company was the first licensed company to launch the generic version of this combination drug earlier in Nepal. The company had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015 to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in 100 other developing countries in addition to India.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×